ClinicalTrials.gg
CompletedNCT01623323Updated Aug 29, 2016Results posted

Study Evaluating the Safety of Intranasal Administration of 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps

A Phase 3 interventional study of Fluticasone Propionate in Chronic Sinusitis With or Without Nasal Polyps, sponsored by Optinose US Inc.. Completed at 18 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-08-29.

Sponsored by Optinose US Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
705
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 83 studies in Nasal Polyps with a site in United States — 13 open to participants now, 20 under way, 8 of them phase 3. Nasal Polyps · United States.

Enrollment
Largest of 71
705 · median 60
Started
2013
with 5 others
Phase 3
25 of 83
4 open now
Registered
9th of 83
by date
Lead sponsor
4 of 83
Optinose US Inc.

Among the 83 studies in Nasal Polyps with a site in United States, this one has the largest enrollment of the 71 interventional ones that give a count, is one of 6 that started in 2013, is one of 25 in phase 3, and was the 9th registered.

Nasal Polyps

236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.

Browse Nasal Polyps studies →

Open to participants now

13 of the 83 studies in Nasal Polyps with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Nasal Polyps with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, multicenter study designed to assess the safety of intranasal administration of 400 μg of fluticasone propionate twice a day delivered by the OptiNose device in subjects with chronic sinusitis with or without nasal polyps. The study consists of an up-to-7-day pretreatment phase followed a 3-month open-label treatment phase. The duration of each subject's participation is approximately 13 weeks.

03

Conditions studied

  • Chronic Sinusitis With or Without Nasal Polyps
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women aged 18 years and older
  • Women must

    • be practicing an effective method of (eg, prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method [eg, condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel], or male partner sterilization) before entry and throughout the study, or
    • be surgically sterile (have had a hysterectomy or bilateral oophorectomy, or tubal ligation at least 1 year before screening) or otherwise be incapable of pregnancy, or
    • be (spontaneous amenorrhea for at least 1 year).
  • Women of must have a negative serum beta-human chorionic gonadotropin (β-hCG) pregnancy test at the screening visit
  • Have either:

a history of chronic sinusitis with bilateral nasal polyposis determined by nasoendoscopy at screening visit OR a history of chronic sinusitis (without polyps) for equal to or greater than 12 weeks and currently experiencing 2 or more of the following symptoms, one of which MUST be either nasal blockage/congestion or nasal discharge (anterior and/or posterior nasal discharge):

  1. nasal blockage/congestion
  2. nasal discharge (anterior and/or posterior nasal discharge)
  3. facial pain or pressure
  4. reduction or loss of smell

    • Subjects with comorbid asthma or must be stable with no exacerbations (eg, no emergency room visits, hospitalizations, or oral or parenteral use) within the 3 months before the screening visit. Inhaled corticosteroid use must be limited to stable doses of no more than 1,000 μg/day of beclomethasone (or equivalent; See Attachment 1) for at least 3 months before screening with plans to continue use throughout the study.
    • Must be able to cease treatment with intranasal steroids and inhaled corticosteroids (except permitted doses listed above for asthma and COPD) at the screening visit
    • Must be able to use the OptiNose device correctly; all subjects will be required to demonstrate correct use of the placebo device at the screening visit, see Section 12.1, Visit 1, screening procedures.
    • Must be capable, in the opinion of the investigator, of providing to participate in the study. Subjects must sign an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or lactating
  • Inability to have each nasal cavity examined for any reason, including nasal septum deviation
  • Nasal septum perforation
  • Has had more than 1 episode of epistaxis with frank bleeding in the month before the screening visit
  • Have evidence of significant baseline mucosal injury, ulceration or erosion (eg, exposed cartilage, perforation) on baseline nasal examination/nasoendoscopy
  • History of sinus or nasal surgery within 6 months before the screening visit
  • Current, ongoing rhinitis medicamentosa (rebound rhinitis)
  • Have significant oral structural abnormalities, eg, a cleft palate
  • Diagnosis of cystic fibrosis
  • History of Churg-Strauss syndrome or dyskinetic ciliary syndromes
  • Purulent nasal infection, acute sinusitis, or upper respiratory tract infection within 2 weeks before the screening visit. Potential subjects presenting with any of these infections may be rescreened 4 weeks after symptom resolution
  • Planned sinonasal surgery during the period of the study
  • Allergy, , or to or steroids
  • Allergy or hypersensitivity to any in study drug
  • Exposure to any glucocorticoid treatment with potential for systemic effects (eg, oral, parenteral, intra-articular, or epidural steroids, high dose topical steroids) within 1 month before the screening visit; except as noted in inclusion criteria for subjects with comorbid asthma or
  • Have nasal candidiasis
  • Have taken a potent inhibitor within 14 days before the screening visit; examples of these medications can be found in Section 11.6, Concomitant Medication.
  • History or current diagnosis of any form of glaucoma or ocular hypertension (ie, intraocular pressure >21 mmHg)
  • History of intraocular pressure elevation on any form of steroid therapy
  • History or current diagnosis of the presence (in either eye) of a cataract
  • Any serious or unstable concurrent disease, psychiatric disorder, or any significant condition that, in the opinion of the investigator could confound the results of the study or could interfere with the subject's participation or compliance in the study
  • A recent (within 1 year of the screening visit) history of drug or alcohol use, abuse, or dependence that, in the opinion of the investigator could interfere with the subject's participation or compliance in the study
  • Positive urine drug screen at screening visit for drugs of abuse (see Section 14.5), with the exception of prescribed medications for legitimate medical conditions
  • Have participated in a previous clinical trial of OPTINOSE FLUTICASONE
  • Have participated in an drug clinical trial within 30 days of the screening visit
  • Employees of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
705 participants (actual)

Study arms

  • Other
    Fluticasone

    Drug: Fluticasone Propionate

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse Events

    Adverse Events were collected via spontaneous subject report and through physician examination. The display of adverse events is by subject.

    Time frame: Baseline to 3 months or End of Study

07

Results

Posted Mar 1, 2016

Participant flow

Participant flow — Overall Study
MilestoneOPN-375
Started705
Completed601
Not completed104

Outcome measures

PrimaryAdverse Events

Adverse Events were collected via spontaneous subject report and through physician examination. The display of adverse events is by subject.

Time frame:
Baseline to 3 months or End of Study
Reported as:
Number · participants
Adverse Events
participantsOPN-375
Adverse Events270

Adverse events

Collected over 3 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OPN-375—5/705 (0.7%)180/705 (25.5%)
Most frequent serious events
Most frequent serious events
EventOPN-375
acute cholecystitisHepatobiliary disorders1/705
Cervix CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/705
Uterine LeiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/705
DyspnoeaRespiratory, thoracic and mediastinal disorders1/705
HypotensionVascular disorders1/705
Most frequent other events
Most frequent other events
EventOPN-375
epistaxisRespiratory, thoracic and mediastinal disorders102/705
Nasal Mucosal DisorderRespiratory, thoracic and mediastinal disorders72/705
Nasal Septal DisorderRespiratory, thoracic and mediastinal disorders39/705

Baseline characteristics

Age, Continuous
Age, Continuous(years)OPN-375
Mean45.3 ± 13.71
Sex: Female, Male
Sex: Female, Male(Participants)OPN-375
Female403
Male302
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)OPN-375
Hispanic or Latino81
Not Hispanic or Latino624
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)OPN-375
American Indian or Alaska Native2
Asian28
Native Hawaiian or Other Pacific Islander3
Black or African American114
White552
More than one race6
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)OPN-375
United States705
08

Study locations

18 sites
  • Precision Trials
    Phoenix, Arizona 85032, United States
  • Colorado ENT and Allergy
    Colorado Springs, Colorado 80909, United States
  • Sher Allergy
    Largo, Florida 33778, United States
  • ENT of Georgia
    Decatur, Georgia 30030, United States
  • Best Clinical Trials
    New Orleans, Louisiana 70115, United States
  • Institute for Asthma and Allergy
    Wheaton, Maryland 20902, United States
  • Clinical Research Group of Montana
    Bozeman, Montana 59718, United States
  • ENT and Allergy Associates
    New Windsor, New York 12553, United States
  • ENT and Allergy Associates
    West Nyack, New York 10994, United States
  • Vital Prospects Clinical Research Institute
    Tulsa, Oklahoma 74136, United States
  • Allergy Associates Research Center
    Portland, Oregon 97202, United States
  • Live Oak Allergy and Asthma Clinic
    Live Oak, Texas 78233, United States
  • Texas Quest Medical Research
    San Antonio, Texas 78256, United States
  • Focus Clinical Research
    Draper, Utah 84020, United States
  • InterMountain Ear Nose and Throat
    Salt Lake City, Utah 84102, United States
  • Chrysalis Clinical Research
    St George, Utah 84790, United States
  • Advanced Clinical Research
    West Jordan, Utah 84088, United States
  • Premier Clinical Research
    Spokane, Washington 99204, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2013, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2016, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2012
First posted
Jun 19, 2012
Start
Sep 2013
Primary completionActual
Mar 2015
CompletionActual
Mar 2015
Results first posted
Mar 1, 2016
Last update
Aug 29, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01623323
Lead sponsor
Optinose US Inc.
Responsible party
Sponsor
First posted
Jun 19, 2012
Start date
Sep 2013
Primary completion
Mar 2015
Completion
Mar 2015
Results posted
Mar 1, 2016
Last update
Aug 29, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone

Start the discussion